Longitudinal Measurements of Blood Biomarkers in Patients with Crohn’s Disease or Ulcerative Colitis Treated with Infliximab: Only the Latest Values in the Induction Period Predict Treatment Failure
<b>Background:</b> Few studies have incorporated longitudinal assessments or used combinations of blood biomarkers as predictors of loss of response to biologic therapy for patients with Crohn’s disease (CD) or ulcerative colitis (UC). <b>Methods:</b> This is a population-bas...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/13/4/926 |
| _version_ | 1797297901290913792 |
|---|---|
| author | Kim Oren Gradel Bente Mertz Nørgård Sonia Friedman Jens Kjeldsen Michael Due Larsen |
| author_facet | Kim Oren Gradel Bente Mertz Nørgård Sonia Friedman Jens Kjeldsen Michael Due Larsen |
| author_sort | Kim Oren Gradel |
| collection | DOAJ |
| description | <b>Background:</b> Few studies have incorporated longitudinal assessments or used combinations of blood biomarkers as predictors of loss of response to biologic therapy for patients with Crohn’s disease (CD) or ulcerative colitis (UC). <b>Methods:</b> This is a population-based cohort study comprising Danish patients with CD or UC from 2008 to 2018. We used logistic regression to analyze whether levels and changes in levels of C-reactive protein (CRP), serum albumin, and hemoglobin, routinely measured during a 14-week infliximab induction period, predicted a change to another biologic medication or cessation of biologic therapy. <b>Results:</b> During the induction period, 2883 (1626 CD, 1257 UC) patients had 12,730, 12,040, and 13,538 specimens with CRP, serum albumin, and hemoglobin, respectively. In all, 284 patients (9.9%) switched to another biologic medication, and 139 (4.8%) ceased biologic therapy in the follow-up period. Only the most recent CRP and hemoglobin levels predicted the efficacy of infliximab treatment at approximately 14 weeks, a time point when the clinician often determines whether to continue treatment. <b>Conclusion:</b> Measurement of blood biomarkers prior to the clinical assessment does not predict the effectiveness of infliximab. |
| first_indexed | 2024-03-07T22:28:02Z |
| format | Article |
| id | doaj.art-d71f85d1d6974c9ba1ec837b88d54e68 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-07T22:28:02Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-d71f85d1d6974c9ba1ec837b88d54e682024-02-23T15:21:48ZengMDPI AGJournal of Clinical Medicine2077-03832024-02-0113492610.3390/jcm13040926Longitudinal Measurements of Blood Biomarkers in Patients with Crohn’s Disease or Ulcerative Colitis Treated with Infliximab: Only the Latest Values in the Induction Period Predict Treatment FailureKim Oren Gradel0Bente Mertz Nørgård1Sonia Friedman2Jens Kjeldsen3Michael Due Larsen4Center for Clinical Epidemiology, Odense University Hospital, 5000 Odense, DenmarkCenter for Clinical Epidemiology, Odense University Hospital, 5000 Odense, DenmarkCenter for Clinical Epidemiology, Odense University Hospital, 5000 Odense, DenmarkDepartment of Medical Gastroenterology S, Odense University Hospital, 5000 Odense, DenmarkCenter for Clinical Epidemiology, Odense University Hospital, 5000 Odense, Denmark<b>Background:</b> Few studies have incorporated longitudinal assessments or used combinations of blood biomarkers as predictors of loss of response to biologic therapy for patients with Crohn’s disease (CD) or ulcerative colitis (UC). <b>Methods:</b> This is a population-based cohort study comprising Danish patients with CD or UC from 2008 to 2018. We used logistic regression to analyze whether levels and changes in levels of C-reactive protein (CRP), serum albumin, and hemoglobin, routinely measured during a 14-week infliximab induction period, predicted a change to another biologic medication or cessation of biologic therapy. <b>Results:</b> During the induction period, 2883 (1626 CD, 1257 UC) patients had 12,730, 12,040, and 13,538 specimens with CRP, serum albumin, and hemoglobin, respectively. In all, 284 patients (9.9%) switched to another biologic medication, and 139 (4.8%) ceased biologic therapy in the follow-up period. Only the most recent CRP and hemoglobin levels predicted the efficacy of infliximab treatment at approximately 14 weeks, a time point when the clinician often determines whether to continue treatment. <b>Conclusion:</b> Measurement of blood biomarkers prior to the clinical assessment does not predict the effectiveness of infliximab.https://www.mdpi.com/2077-0383/13/4/926blood biomarkerslongitudinal measurementsinfliximabpredictionCrohn’s diseaseulcerative colitis |
| spellingShingle | Kim Oren Gradel Bente Mertz Nørgård Sonia Friedman Jens Kjeldsen Michael Due Larsen Longitudinal Measurements of Blood Biomarkers in Patients with Crohn’s Disease or Ulcerative Colitis Treated with Infliximab: Only the Latest Values in the Induction Period Predict Treatment Failure Journal of Clinical Medicine blood biomarkers longitudinal measurements infliximab prediction Crohn’s disease ulcerative colitis |
| title | Longitudinal Measurements of Blood Biomarkers in Patients with Crohn’s Disease or Ulcerative Colitis Treated with Infliximab: Only the Latest Values in the Induction Period Predict Treatment Failure |
| title_full | Longitudinal Measurements of Blood Biomarkers in Patients with Crohn’s Disease or Ulcerative Colitis Treated with Infliximab: Only the Latest Values in the Induction Period Predict Treatment Failure |
| title_fullStr | Longitudinal Measurements of Blood Biomarkers in Patients with Crohn’s Disease or Ulcerative Colitis Treated with Infliximab: Only the Latest Values in the Induction Period Predict Treatment Failure |
| title_full_unstemmed | Longitudinal Measurements of Blood Biomarkers in Patients with Crohn’s Disease or Ulcerative Colitis Treated with Infliximab: Only the Latest Values in the Induction Period Predict Treatment Failure |
| title_short | Longitudinal Measurements of Blood Biomarkers in Patients with Crohn’s Disease or Ulcerative Colitis Treated with Infliximab: Only the Latest Values in the Induction Period Predict Treatment Failure |
| title_sort | longitudinal measurements of blood biomarkers in patients with crohn s disease or ulcerative colitis treated with infliximab only the latest values in the induction period predict treatment failure |
| topic | blood biomarkers longitudinal measurements infliximab prediction Crohn’s disease ulcerative colitis |
| url | https://www.mdpi.com/2077-0383/13/4/926 |
| work_keys_str_mv | AT kimorengradel longitudinalmeasurementsofbloodbiomarkersinpatientswithcrohnsdiseaseorulcerativecolitistreatedwithinfliximabonlythelatestvaluesintheinductionperiodpredicttreatmentfailure AT bentemertznørgard longitudinalmeasurementsofbloodbiomarkersinpatientswithcrohnsdiseaseorulcerativecolitistreatedwithinfliximabonlythelatestvaluesintheinductionperiodpredicttreatmentfailure AT soniafriedman longitudinalmeasurementsofbloodbiomarkersinpatientswithcrohnsdiseaseorulcerativecolitistreatedwithinfliximabonlythelatestvaluesintheinductionperiodpredicttreatmentfailure AT jenskjeldsen longitudinalmeasurementsofbloodbiomarkersinpatientswithcrohnsdiseaseorulcerativecolitistreatedwithinfliximabonlythelatestvaluesintheinductionperiodpredicttreatmentfailure AT michaelduelarsen longitudinalmeasurementsofbloodbiomarkersinpatientswithcrohnsdiseaseorulcerativecolitistreatedwithinfliximabonlythelatestvaluesintheinductionperiodpredicttreatmentfailure |